INTERVIEW: Pyott maps Botox and beyond path for 'growth junky' Allergan
This article was originally published in Scrip
Executive Summary
Allergan chairman, president and CEO David Pyott has set a goal of 10% revenue growth per year, but he isn't picky about where it comes from - therapeutics, aesthetics or medical devices - as long as the assets are differentiated from competing products in a way that they drive long-term revenue growth.